AUPH vs BMY
AUPH: Aurinia Pharmaceuticals is a biopharmaceutical company commercializing LUPKYNIS, a targeted treatment for lupus nephritis. BMY: A leading biopharmaceutical innovator focused on discovering and delivering life-changing medicines to address serious illnesses globally.
Side-by-side fundamentals
| Metric | AUPH | BMY | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $16.74 | $61.68 | |
| Market cap | $2.2B | $126.0B | |
| P/E as of 2026-10-20 | 7.34 | 13.59 | AUPH lower |
| Net margin FY2025, SEC XBRL | n/a | +14.6% | |
| Operating margin FY2025, SEC XBRL | +37.1% | n/a | |
| ROE FY2025, SEC XBRL | +49.4% | +38.2% | AUPH higher |
| ROA FY2025, SEC XBRL | +38.2% | +7.8% | AUPH higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | n/a | 1.97 | |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | -0.2% | |
| Revenue CAGR (3y) SEC XBRL | +28.3% | +1.4% | AUPH higher |
| Dividend yield as of 2026-09-03 | n/a | +4.0% | |
| Dividend streak (yrs) SEC XBRL | 0 | 19 | BMY higher |
| Beta as of 2026-09-03 | 0.67 | 0.25 | |
| 1-year return as of 2026-10-20 close | +41.4% | +41.5% | BMY higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.